Analysts are comparing this stellar run with the surge that Ruchi Soya shares saw after Ramdev’s Patanjali Group acquired the company last ...

Shares of Orchid closed at Rs 17 on Friday, down 5 per cent.

As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.

USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determine...

Chennai-based Orchid Pharma has received final approval from the US health regulator for its generic version of rasagiline tablets.

Orchid Chemicals and Pharmaceuticals Ltd has said its Cephalosporin API manufacturing (antibiotic) complex in Alathur, Chennai, has success...

Orchid Chemicals is all set to buy US based Karalex Pharma. The acquisition is likely to be completed this month.

Pharma firm Orchid Chemicals & Pharmaceuticals today said it has received the US drug regulator's nod for its Piperacillin and Tazobactam i...

Drugmaker Orchid Chemicals, party to hectic share purchase activities by a Ranbaxy group entity recently, is attracting a new investor -- P...

Ranbaxy said the pact with Orchid involved multiple geographies and therapies for both finished dosage forms and active pharmaceutical ingr...

Orchid Chemicals’ shares plunged 12.5% or Rs 40 to Rs 279 on Thursday from Wednesday’s close of Rs 319 at BSE.

The Ranbaxy Group has come within striking distance of an open offer for Chennai-based drug maker Orchid Chemicals & Pharmaceuticals.

Ranbaxy, which has been linked to a hostile takeover bid of Orchid Chemicals, has said it does not believe in such practices.

Solrex will have to fork out an extra Rs 400-500 crore to buy a further 20% stake in case it comes with an open offer.

As a proxy fight for the control of drug maker Orchid intensifies in the stock market, a key weapon in founder K Raghavendra Rao’s arsenal ...

A creeping acquisition has begun in the shares of Chennai-based Orchid Chemicals & Pharmaceuticals which has become vulnerable to acquisiti...

After the high-profile Mylan-Matrix deal, private equity firms are emerging as major catalysts in domestic pharma M&As.